Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Potential screening model for tissue specific calcium channel blockers]

Claudia Seisenberger1, Franz Hofmann

  • 1Institut für Pharmakologie und Toxikologie der Technischen Universität München, D-München.

ALTEX
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential segment-specific signalling pathways for guanylate cyclase C-activated anion secretion in murine ileocolon.

British journal of pharmacology·2025
Same author

New treatment for pyridoxine-dependent epilepsy due to ALDH7A1 deficiency: first proof-of-principle of upstream enzyme inhibition in the mouse.

Brain communications·2025
Same author

Loss of histone macroH2A1.1 causes kidney abnormalities secondary to a change in nutrient metabolization.

Science advances·2025
Same author

Corrigendum to "Protein synthesis inhibition promotes nitric oxide generation and activation of CGKII-dependent downstream signaling pathways in the retina" [Biochim. Biophys. Acta (BBA) Mol. Cell Res. 1867 (2020) 118732 10.1016/j.bbamcr.2020.118732].

Biochimica et biophysica acta. Molecular cell research·2025
Same author

Loss of Ten1 in mice induces telomere shortening and models human dyskeratosis congenita.

Science advances·2025
Same author

cGMP-dependent kinase 2, Na<sup>+</sup>/H<sup>+</sup> exchanger NHE3, and PDZ-adaptor NHERF2 co-assemble in apical membrane microdomains.

Acta physiologica (Oxford, England)·2024

Researchers developed cell lines for specific cardiac and smooth muscle calcium channels. These cell lines aid in screening for targeted cardiovascular disease therapies and developing tissue-specific drugs.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Cardiovascular diseases remain a leading cause of mortality in industrialized nations.
  • Current therapeutic strategies for cardiovascular diseases require enhancement, particularly regarding tissue specificity.
  • L-type calcium channels are critical in cardiac and smooth muscle function and are targets for drug development.

Purpose of the Study:

  • To establish cell lines that express tissue-specific L-type calcium channels (cardiac and smooth muscle).
  • To investigate the differences in the IS6 segment of the alphaIC-gene in cardiac versus smooth muscle L-type calcium channels.
  • To create a platform for screening tissue-specific calcium channel blockers.

Main Methods:

  • Genetic engineering to create cell lines expressing specific splice variants of the alphaIC-gene (alphaIC-a and alphaIC-b).

Related Experiment Videos

  • Characterization of cell lines for expression of cardiac and smooth muscle L-type calcium channels.
  • Utilizing established cell lines for screening potential drug candidates.

    • Main Results:

    • Successfully established cell lines expressing either cardiac or smooth muscle L-type calcium channels.
    • Identified differences in the IS6 segment of the alphaIC-gene correlating with tissue specificity.
    • Demonstrated the utility of these cell lines for screening purposes.

    Conclusions:

    • The developed cell lines provide a valuable tool for identifying tissue-specific calcium channel blockers.
    • This approach can facilitate the development of improved therapies for cardiovascular diseases.
    • Targeting specific L-type calcium channel variants offers a promising strategy for enhanced drug efficacy and reduced side effects.